The SELECT trial demonstrated that Wegovy 2.4 mg also reduces the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight
139 PattingreS.TassaA.QuX.GarutiR.XiaoH
A esto se suma que, como sucede con otros frmacos, no todos responden igual , dice la endocrinloga
In this study, obesity did not promote prostate tumorigenicity and no differences between lean and obese mice were observed in tumor progression and in the expressions of homeobox protein Nkx-3.1, androgen receptor, and prostate-specific antigen
and collision energy, 35 15 V
And it is currently being studied for heart failure with preserved ejection fraction (HFpEF), cardiovascular risk reduction, and metabolic dysfunction-associated steatohepatitis (MASH), etc